| Title: | Dynamic phenotypes of preclinical and clinical obesity in relation to new-onset cancer risk: A longitudinal analysis from the UK biobank |
| Journal: | Diabetes Obesity and Metabolism |
| Published: | 2 Jul 2025 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/40605151/ |
| DOI: | https://doi.org/10.1111/dom.16582 |
| URL: | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.16582 |
Publication 16350
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
AIM: The definition of clinical obesity was newly announced. Our study aims to investigate the relationship between different states of obesity and dysfunctions due to obesity with cancer incidence and mortality.</p>
METHODS: The prospective cohort study from the UK Biobank included 220 016 participants. Anthropometric parameters, in combination with obesity-induced dysfunctions, were used to diagnose clinical obesity. Six clusters were categorized according to individual's baseline and follow-up dysfunction status. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for cancer incidence risk were estimated using the landmark analysis.</p>
RESULTS: After a mean follow-up period of 11.0 years, a total of 24 066 cancer incidence was observed. Using Cluster 1 (participants without obesity and dysfunction at baseline and during follow-up) as the reference group, Cluster 5 (preclinical obesity with follow-up dysfunctions; HR = 3.17, 95% CI: 3.05-3.29) exhibited the highest multivariable-adjusted cancer incidence risk, while Cluster 4 (preclinical obesity without follow-up dysfunctions; HR = 0.88, 95% CI: 0.85-0.92) showed the lowest. Additionally, the fully adjusted HRs for cancer mortality showed the highest in Cluster 6 (clinical obesity; HR = 1.82, 95% CI: 1.65-2.00), compared with Cluster 1. Site-specific analyses showed consistently higher cancer risks in Cluster 5 and 6 across various types of cancer, notably the incidence of pancreatic cancer and the mortality of prostate or bladder cancer.</p>
CONCLUSION: Obesity-induced dysfunction was significantly associated with cancer risk. For future clinical practice, the early identification and intervention of clinical obesity and obesity-induced dysfunctions are of critical importance for reducing cancer risks.</p>
17 Keywords
- Adult
- Aged
- Biological Specimen Banks
- Body Mass Index
- Female
- Humans
- Incidence
- Longitudinal Studies
- Male
- Middle Aged
- Neoplasms
- Obesity
- Phenotype
- Prospective Studies
- Risk Factors
- UK Biobank
- United Kingdom
6 Authors
- Manrong Xu
- Menghan Li
- Yawen Zhang
- Lianxi Li
- Yun Shen
- Gang Hu
1 Application
| Application ID | Title |
|---|---|
| 177053 | Assessing and Mitigating Major Adverse Liver Outcomes among patients with metabolic-associated steatotic liver diseases: risk factor analysis based on multi-dimensional data |
Enabling scientific discoveries that improve human health